Karen Aiach

Karen Aiach is a Senior Advisor and a pioneering entrepreneur in the field of rare diseases. She is the Founder and former CEO of Lysogene (Euronext: LYS), a clinical-stage gene therapy company focused on transformative treatments for orphan diseases of the central nervous system (CNS). Under her leadership, Lysogene developed a leading gene therapy platform to address neurodegenerative lysosomal storage disorders.

Karen’s relentless advocacy and expertise in orphan drug development have made her a global authority in the field. Her strategic vision was instrumental in expanding Lysogene’s pipeline and establishing critical partnerships with patient advocacy groups. In 2015, she was honored with the W.I.T.H. (Women Innovating Together in Healthcare) Woman of the Year Award, and in 2016, she was invited to present her journey at Harvard Business School.

A graduate of ESSEC Business School with a major in Economics, Karen is deeply committed to accelerating scientific breakthroughs for patients with high unmet medical needs. Her unique perspective as both an industry leader and a mother of a child with a rare genetic disorder brings an unmatched level of empathy and strategic urgency to her advisory roles.